Drug intelligence / Profile preview

PF-07941944

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-07941944 is an investigational small molecule antiviral drug being developed by Pfizer for the treatment of respiratory syncytial virus (RSV) infections. As of June 2025, it is classified as a new molecular entity and is in Phase 1 clinical trials. The precise mechanism of action has not been publicly disclosed, but it is categorized broadly as an antiviral agent targeting RSV. Clinical studies are currently focused on evaluating its safety, tolerability, and pharmacokinetics in healthy adult participants[1][2][3][4][5][7].

Beyond the preview

Go deeper on PF-07941944.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07941944.

Explore the full profile